Does rapid dose titration affect the hepatic safety profile of Bosentan?

Vascular Pharmacology

Volumn 44, Issue 6, 2006, Pages 508-512

  Suntharalingam, J ^a   Hodgkins, D ^a   Cafferty, F H ^b   Hughes, R J ^a   Pepke Zaba, J ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

Bosentan; Hepatic dysfunction; Pulmonary hypertension; Rapid titration

Indexed keywords

ALANINE AMINOTRANSFERASE; ALENDRONIC ACID; AMLODIPINE; ATORVASTATIN; BECLOMETASONE; BOSENTAN; CODANTHRAMER; DOMPERIDONE; DOSULEPIN; ENDOTHELIN RECEPTOR ANTAGONIST; ERGOCALCIFEROL; FLUTICASONE; FUROSEMIDE; HUMAN INSULIN; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LANSOPRAZOLE; LOSARTAN; MORPHINE SULFATE; NICARDIPINE; OMEPRAZOLE; PANTOPRAZOLE; PERINDOPRIL; PREDNISOLONE; RANITIDINE; THYROXINE; TIBOLONE; TRAMADOL; TRIMETHOPRIM; UNINDEXED DRUG; WARFARIN;

ADULT; AGED; ARTICLE; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG SAFETY; FEMALE; HEART INDEX; HEART RIGHT ATRIUM PRESSURE; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK ASSESSMENT; THROMBOEMBOLISM;

ALANINE TRANSAMINASE; ANTIHYPERTENSIVE AGENTS; CONNECTIVE TISSUE DISEASES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33747313771     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.03.004     Document Type: Article

References (13)

1. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 9288 (2001) 1119-1123
2. Fattinger K., Funk C., Pantze M., et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69 4 (2001) 223-231
3. Girgis R.E., Mathai S.C., Krishnan J.A., Wigley F.M., and Hassoun P.M. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J. Heart Lung Transplant. 24 10 (2005) 1626-1631
4. Hill N.S., Warburton R.R., Pietras L., and Klinger J.R. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J. Appl. Physiol. 83 4 (1997) 1209-1215
5. Humbert M., Kiely D.G., Carlsen J., van Lierop C., and Hoeper M.M. Long-term safety profile of Bosentan in patients with pulmonary arterial hypertension: results from the European surveillance program. American Thoracic Society conference, San Diego (2005) A300
6. McCulloch K.M., Docherty C., and MacLean M.R. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. Br. J. Pharmacol. 123 8 (1998) 1621-1630
7. Pearl J.M., Wellmann S.A., McNamara J.L., et al. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. Ann. Thorac. Surg. 68 5 (1999) 1714-1721
8. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346 12 (2002) 896-903
9. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43 12 Suppl S (2004) 5S-12S
10. Sutsch G., Kiowski W., Yan X.W., et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98 21 (1998) 2262-2268
11. Weber C., Schmitt R., Birnboeck H., et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J. Clin. Pharmacol. 39 7 (1999) 703-714
12. www.fda.gov/medwatch/SAFETY/2003/03Oct_PI/Tracleer_PI.pdf.
13. Youssef W.I., and Tavill A.S. Connective tissue diseases and the liver. J. Clin. Gastroenterol. 35 4 (2002) 345-349